Desert King
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español
La Opción Natural La Opción Natural La Opción Natural La Opción Natural
  • Nosotros
  • Materias Primas
    • Administración de Materias Primas: Quillaja
    • Administración de Materias Primas: Yucca
    • Administración de Materias Primas: Jojoba
  • Líneas de Negocio
    • Farmacéutica
    • Nutrición y Salud Animal
    • Alimentación y Bebidas
    • Cuidado Personal y Cosmética
    • Agricultura
    • Medio ambiente y minería
  • Calidad
  • Noticias
  • Canal de Denuncias
  • Contacto
  • Inglés
  • Español

Archives

 Desert King leads quillay traceability and sustainable management with FSC® certification 
0
By Desert King
In Publicaciones
Posted 25 septiembre, 2025

Desert King leads quillay traceability and sustainable management with FSC® certification 

Responsible Management:  Desert King leads quillay traceability and sustainable management with FSC® certification  The company is the only one in the quillay industry to hold FSC® Chain of [...]

READ MORE
 Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China

Recbio Technology is conducting a Phase 3 clinical trial for its novel adjuvanted recombinant shingles vaccine REC610 in China. Jiangsu Recbio Technology Co., Ltd. is pleased to announce that the [...]

READ MORE
 Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192.

Destexhe, E. A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines. NPJ Vaccines, 2025 Aug 13, 10(1):192. PMID: 40804241 This study supports a [...]

READ MORE
 Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30.

Valadares, D.G., et al. LeishTec vaccination disrupts vertical transmission of Leishmania infantum. PLoS Negl Trop Dis, 2025 Jul 30. PMID: 40737310 LeishTec is a recombinant vaccine adjuvanted [...]

READ MORE
 Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396.

Chan, C.C.Y., et al. AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults. Vaccine, 2025 Aug 13, 61:127396. PMID: 40592255 This study [...]

READ MORE
 Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, 61:127362.

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, [...]

READ MORE
 Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.
0
By Desert King
In Texto Cientifico
Posted 15 septiembre, 2025

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, 10(1):184.

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, [...]

READ MORE

DESERT KING INTERNATIONAL
745 Main Street-
Chula Vista, CA, USA, 91911
+1 619 429 5222
info@desertking.com

DESERT KING CHILE
Avenida Industrial 1970
Quilpué, Chile, 2420505
+56 32 292 5020
info@desertking.cl

DESERT KING MEXICO
Camino Vecinal 11500-A
Tijuana B.C., México, 22664
+52 664 636 11 24
info@desertkingmexico.com

Politica de Privacidad
© 2025 Desert King. All Right Reserved

Start typing and press Enter to search